G
Monte Rosa Therapeutics D
D
GLUE
16.370
USD
-1.00
(-5.76%)
Post Trading·17.200USD+0.830(+5.07%)
حجم التداول
38,643
الربح لكل سهم
-1
العائد الربحي
-
P/E
-11
حجم السوق
1,382,928,073
المقالات
العنوان: Monte Rosa Therapeutics
القطاع: Healthcare
الصناعة: Biotechnology
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programsin clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).